- Home
- CHI vs INSP Comparison
CHI vs INSP Comparison
Compare CHI & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | INSP |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2002 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CHI | INSP |
|---|---|---|
| Price | $13.47 | $52.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $94.00 |
| AVG Volume (30 Days) | 191.8K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.02 |
| Revenue Next Year | N/A | $8.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $10.10 | $38.91 |
| 52 Week High | $13.50 | $147.03 |
Technical Indicators
Market Signals| Indicator | CHI | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 63.91 | 72.13 |
| Support Level | $12.48 | $48.30 |
| Resistance Level | $13.48 | $58.45 |
| Average True Range (ATR) | 0.27 | 2.22 |
| MACD | 0.00 | 1.06 |
| Stochastic Oscillator | 96.66 | 97.48 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.